• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在闭塞治疗阶段体内原卟啉IX荧光积累的定量研究。

A quantitative study of in vivo protoporphyrin IX fluorescence build up during occlusive treatment phases.

作者信息

Campbell C Louise, Brown C Tom A, Wood Kenneth, Salvio Ana Gabriela, Inada Natalia M, Bagnato Vanderlei S, Moseley Harry

机构信息

SUPA, School of Physics and Astronomy, University of St Andrews, UK.

Skin Department of Amaral Carvalho Hospital, Brazil.

出版信息

Photodiagnosis Photodyn Ther. 2017 Jun;18:204-207. doi: 10.1016/j.pdpdt.2017.02.004. Epub 2017 Feb 28.

DOI:10.1016/j.pdpdt.2017.02.004
PMID:28257944
Abstract

BACKGROUND

Topical photodynamic therapy (PDT) is a non-invasive light based therapy used to treat non-melanoma skin cancer (NMSC) and dysplasia. During PDT, the light sensitive molecule protoporphyrin IX (PpIX) is activated, resulting in the production of singlet oxygen, which subsequently leads to cell death. PpIX is metabolised from a topically applied pro-drug and the strong fluorescence signal associated with PpIX can be utilised as an indicator of the amount of PpIX present within the tumour tissue. In this work we measure the build up PpIX during the occlusive treatment phase and investigate how the PpIX production rate is affected by different lesion and patient characteristics.

METHODS

Fluorescence measurements were used to investigate the build up of PpIX within the tumour tissue during the 3h long occlusive treatment prior to irradiation. The study included in vivo measurements of 38 lesions from 38 individual patients. Actinic keratosis (AK) and basal cell carcinoma (BCC) were the lesion types included in this study. The resulting data from the study was analysed using generalised linear mixed effects models.

RESULTS

It was found that the surface fluorescence signal linearly increased with occlusive treatment time. The predictive models suggest that there is a significant difference in PpIX production between lesion location, however no significant difference is demonstrated between different lesion types, gender and skin type.

CONCLUSIONS

The study extends and supports previous knowledge of PpIX production during the occlusive treatment phase.

摘要

背景

局部光动力疗法(PDT)是一种用于治疗非黑色素瘤皮肤癌(NMSC)和发育异常的非侵入性光基疗法。在PDT过程中,光敏分子原卟啉IX(PpIX)被激活,产生单线态氧,随后导致细胞死亡。PpIX由局部应用的前体药物代谢而来,与PpIX相关的强荧光信号可作为肿瘤组织中PpIX含量的指标。在这项工作中,我们测量了封闭治疗阶段PpIX的积累,并研究了PpIX产生率如何受到不同病变和患者特征的影响。

方法

在照射前3小时的封闭治疗期间,使用荧光测量来研究肿瘤组织中PpIX的积累。该研究包括对38名个体患者的38个病变进行体内测量。光化性角化病(AK)和基底细胞癌(BCC)是本研究中包含的病变类型。使用广义线性混合效应模型分析该研究的结果数据。

结果

发现表面荧光信号随封闭治疗时间线性增加。预测模型表明,病变位置之间PpIX的产生存在显著差异,然而不同病变类型、性别和皮肤类型之间未显示出显著差异。

结论

该研究扩展并支持了先前关于封闭治疗阶段PpIX产生的知识。

相似文献

1
A quantitative study of in vivo protoporphyrin IX fluorescence build up during occlusive treatment phases.在闭塞治疗阶段体内原卟啉IX荧光积累的定量研究。
Photodiagnosis Photodyn Ther. 2017 Jun;18:204-207. doi: 10.1016/j.pdpdt.2017.02.004. Epub 2017 Feb 28.
2
Monitoring the accumulation and dissipation of the photosensitizer protoporphyrin IX during standard dermatological methyl-aminolevulinate photodynamic therapy utilizing non-invasive fluorescence imaging and quantification.利用无创荧光成像和定量技术监测标准皮肤科氨甲酰基乙酸甲酯光动力疗法中光敏剂原卟啉 IX 的积累和消散。
Photodiagnosis Photodyn Ther. 2011 Mar;8(1):30-8. doi: 10.1016/j.pdpdt.2010.11.001. Epub 2010 Dec 17.
3
Development of a handheld fluorescence imaging device to investigate the characteristics of protoporphyrin IX fluorescence in healthy and diseased skin.开发一种手持式荧光成像设备,以研究健康和患病皮肤中原卟啉IX荧光的特性。
Photodiagnosis Photodyn Ther. 2015 Dec;12(4):630-9. doi: 10.1016/j.pdpdt.2015.10.002. Epub 2015 Oct 20.
4
Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites.比较肢端和非肢端部位皮肤肿瘤在甲氨基酮戊酸光动力疗法中卟啉IX 的积累和破坏。
Br J Dermatol. 2011 Jun;164(6):1362-8. doi: 10.1111/j.1365-2133.2011.10265.x. Epub 2011 May 13.
5
Protoporphyrin IX formation after application of methyl aminolevulinate on the face and scalp with and without prior curettage.甲氨基酮戊酸涂敷于面部和头皮后,无论是否先进行刮除术,原卟啉 IX 的形成情况。
Photodiagnosis Photodyn Ther. 2018 Jun;22:155-157. doi: 10.1016/j.pdpdt.2018.03.008. Epub 2018 Mar 27.
6
Fluorescence characteristics and pharmacokinetic properties of a novel self-adhesive 5-ALA patch for photodynamic therapy of actinic keratoses.一种用于光动力治疗光化性角化病的新型自粘性5-氨基乙酰丙酸贴片的荧光特性和药代动力学性质
Arch Dermatol Res. 2008 Feb;300(2):53-60. doi: 10.1007/s00403-007-0787-0. Epub 2007 Oct 25.
7
Validation of a non-invasive fluorescence imaging system to monitor dermatological PDT.验证一种非侵入式荧光成像系统以监测皮肤科 PDT 治疗。
Photodiagnosis Photodyn Ther. 2010 Jun;7(2):86-97. doi: 10.1016/j.pdpdt.2010.03.002. Epub 2010 Apr 24.
8
Monte Carlo modeling of in vivo protoporphyrin IX fluorescence and singlet oxygen production during photodynamic therapy for patients presenting with superficial basal cell carcinomas.对患有浅表基底细胞癌的患者进行光动力治疗时,体内原卟啉 IX 荧光和单线态氧产生的蒙特卡罗建模。
J Biomed Opt. 2011 Apr;16(4):048002. doi: 10.1117/1.3562540.
9
The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome.实时皮肤氨基酮戊酸光动力疗法(MAL-PDT)期间原卟啉IX光漂白与后续临床结果之间的关系。
Lasers Surg Med. 2010 Sep;42(7):613-9. doi: 10.1002/lsm.20943.
10
The effects of protoporphyrin IX-induced photodynamic therapy with and without iron chelation on human squamous carcinoma cells cultured under normoxic, hypoxic and hyperoxic conditions.原卟啉 IX 诱导的光动力疗法联合与不联合铁螯合作用对常氧、低氧和高氧条件下培养的人鳞状癌细胞的影响。
Photodiagnosis Photodyn Ther. 2013 Dec;10(4):575-82. doi: 10.1016/j.pdpdt.2013.06.006. Epub 2013 Aug 8.

引用本文的文献

1
Long Term Effectiveness of Photodynamic Therapy for CIN Treatment.光动力疗法治疗CIN的长期疗效
Pharmaceuticals (Basel). 2019 Jul 12;12(3):107. doi: 10.3390/ph12030107.